肝疾患診断の世界市場2020-2026:エンドユーザー別(病院、研究所、その他)、診断技術別、地域別

◆英語タイトル:Global Liver Disease Diagnostics Market By End User (Hospitals, Laboratories and Other End Users), By Diagnosis Technique (Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques), By Region, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT063
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年6月30日
◆ページ数:173
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、イギリス、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、アラブ首長国連邦、サウジアラビア、南アフリカ、ナイジェリア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD3,600 ⇒換算¥388,800見積依頼/購入/質問フォーム
Global License(法人利用)USD6,048 ⇒換算¥653,184見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、肝疾患診断の世界市場について、市場範囲・調査手法、市場概要、エンドユーザー別(病院、研究所、その他)分析、診断技術別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・肝疾患診断の世界市場規模:エンドユーザー別(病院、研究所、その他)
・肝疾患診断の世界市場規模:診断技術別
・肝疾患診断の世界市場規模:地域別
・企業概要
【レポートの概要】

The Global Liver Disease Diagnostics Market size is expected to reach $40.7 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. The liver is a vital organ that primarily functions to metabolize and detoxify toxic substances that may be harmful to the body. Liver disease refers to any illness that induces inflammation of the liver and may interfere with the proper functioning of the liver. The causes of liver disease include infection, autoimmune disorders, excessive-intake of drugs, injury, alcohol consumption, among others.

Liver diseases impact millions of people all over the world. In most developing nations, the prevalence of viral hepatitis is increasing as a result of modern advances in disease prevention, diagnosis, and treatment. Extended programs for systematic vaccination against the hepatitis B virus have also significantly reduced the number of new cases in many countries.

On the contrary, with better living conditions, the prevalence of the chronic liver disease, including non-alcoholic fatty liver disease and alcohol-related liver disease, is expected to escalate, potentially leading to more cases of end-stage liver disease (liver failure, cirrhosis, and liver cancer). During the last 30 years, visionary governments of major nations have given clear incentives for basic/clinical research, vaccination services, and drug discovery and production in the field of hepatology.

Changing habits, such as increased alcohol intake, unhealthy diets, have increased the occurrence of liver disease. Furthermore, the increasing geriatric population has contributed to significant growth in the global demand for the treatment of liver disease. There is a significant market opportunity for this market because the prevalence of disorders has become common. Government and non-government awareness programs will contribute to the growth of the liver disease treatment industry.

Nonetheless, stringent government regulations (FDA, MHRA), high prices of drug research and development, pose a crucial challenge to the liver disease treatment industry. Side effects associated with medications are a growing concern that consumer demand is expected to decline. Patent expiry and increasing general awareness of health will promote the development of the sector. New research and technology would create an immense opportunity for market players.

Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.

Strategies deployed in Liver Disease Diagnostics Market

Mar-2020: Roche announced that it received the US Food and Drug Administration (FDA) breakthrough device designation for its Elecsys GALAD score, a serum biomarker-based model. This model can predict hepatocellular carcinoma in chronic liver disease patients.
Jan-2020: Siemens launched the enhanced liver fibrosis (ELF) testing service in United States. The ELF test provides a simple, unitless numeric score via an algorithm by combining the quantitative measurements in a serum sample of three direct markers of liver fibrosis: aminoterminal propeptide of type III procollagen (PIIINP), hyaluronic acid (HA), and tissue inhibitor of metalloproteinase 1 (TIMP-1).
Nov-2019: Siemens collaborated with Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins. The collaboration was focused on nonalcoholic steatohepatitis (NASH) and liver fibrosis. This collaboration enabled Siemens Healthineers to use Galectin’s Phase 2 NASH-CX clinical trial to support regulatory filings of the ADVIA Centaur® Enhanced Liver Fibrosis (ELF) test.
Aug-2019: Boston Scientific completed the acquisition of BTG PLC, a company that develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. The acquisition enabled it to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world.
Feb-2019: Abbott got CE Mark for the world’s most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine HBsAg 2 test. This highly sensitive, easy-to-use, rapid lateral flow test enabled identification of those with the virus and facilitates linkage to care in every healthcare setting. Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV).
Dec-2017: Siemens Healthineers signed an agreement to acquire Fast Track Diagnostics (FTD), a global supplier of diagnostics tests. The acquisition would strengthen and expand its presence in the field of molecular testing and precision medicine.
Oct-2017: Abbott acquired Alere, a company that provides diagnostics and point of care solutions. The acquisition helped Abbott in becoming the global leader in point of care testing, the fastest-growing segment in vitro diagnostics market. It also strengthened the company’s diagnostics presence.
Aug-2017: Abbott signed an agreement with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. The agreement was focused on supplying all analytical equipment and consumables. The agreement included Abbott’s Alinity ci and Alinity h series of diagnostic instruments, as well as the company’s professional services and informatics solutions known as AlinIQ.

Scope of the Study
Market Segmentation:

By End User
• Hospitals, Laboratories and Other End Users

By Diagnosis Technique
• Imaging
• Biopsy
• Endoscopy
• Laboratory tests and
• Other Diagnosis Techniques

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Boston Scientific Corporation
• Siemens AG (Siemens Healthineers)
• Bayer AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Pfizer, Inc.
• Randox laboratories limited

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Liver Disease Diagnostics Market, by End User
1.4.2 Global Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 Global Liver Disease Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Liver Disease Diagnostics Market by End User
3.1 Global Hospitals Market by Region
3.2 Global Laboratories Market by Region
3.3 Global Other End Users Market by Region
Chapter 4. Global Liver Disease Diagnostics Market by Diagnosis Technique
4.1 Global Imaging Market by Region
4.2 Global Biopsy Market by Region
4.3 Global Endoscopy Market by Region
4.4 Global Laboratory tests Market by Region
4.5 Global Other Diagnosis Techniques Market by Region
Chapter 5. Global Liver Disease Diagnostics Market by Region
5.1 North America Liver Disease Diagnostics Market
5.1.1 North America Liver Disease Diagnostics Market by End User
5.1.1.1 North America Hospitals Market by Country
5.1.1.2 North America Laboratories Market by Country
5.1.1.3 North America Other End Users Market by Country
5.1.2 North America Liver Disease Diagnostics Market by Diagnosis Technique
5.1.2.1 North America Imaging Market by Country
5.1.2.2 North America Biopsy Market by Country
5.1.2.3 North America Endoscopy Market by Country
5.1.2.4 North America Laboratory tests Market by Country
5.1.2.5 North America Other Diagnosis Techniques Market by Country
5.1.3 North America Liver Disease Diagnostics Market by Country
5.1.3.1 US Liver Disease Diagnostics Market
5.1.3.1.1 US Liver Disease Diagnostics Market by End User
5.1.3.1.2 US Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.2 Canada Liver Disease Diagnostics Market
5.1.3.2.1 Canada Liver Disease Diagnostics Market by End User
5.1.3.2.2 Canada Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.3 Mexico Liver Disease Diagnostics Market
5.1.3.3.1 Mexico Liver Disease Diagnostics Market by End User
5.1.3.3.2 Mexico Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.4 Rest of North America Liver Disease Diagnostics Market
5.1.3.4.1 Rest of North America Liver Disease Diagnostics Market by End User
5.1.3.4.2 Rest of North America Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Europe Liver Disease Diagnostics Market
5.2.1 Europe Liver Disease Diagnostics Market by End User
5.2.1.1 Europe Hospitals Market by Country
5.2.1.2 Europe Laboratories Market by Country
5.2.1.3 Europe Other End Users Market by Country
5.2.2 Europe Liver Disease Diagnostics Market by Diagnosis Technique
5.2.2.1 Europe Imaging Market by Country
5.2.2.2 Europe Biopsy Market by Country
5.2.2.3 Europe Endoscopy Market by Country
5.2.2.4 Europe Laboratory tests Market by Country
5.2.2.5 Europe Other Diagnosis Techniques Market by Country
5.2.3 Europe Liver Disease Diagnostics Market by Country
5.2.3.1 Germany Liver Disease Diagnostics Market
5.2.3.1.1 Germany Liver Disease Diagnostics Market by End User
5.2.3.1.2 Germany Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.2 UK Liver Disease Diagnostics Market
5.2.3.2.1 UK Liver Disease Diagnostics Market by End User
5.2.3.2.2 UK Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.3 France Liver Disease Diagnostics Market
5.2.3.3.1 France Liver Disease Diagnostics Market by End User
5.2.3.3.2 France Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.4 Russia Liver Disease Diagnostics Market
5.2.3.4.1 Russia Liver Disease Diagnostics Market by End User
5.2.3.4.2 Russia Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.5 Spain Liver Disease Diagnostics Market
5.2.3.5.1 Spain Liver Disease Diagnostics Market by End User
5.2.3.5.2 Spain Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.6 Italy Liver Disease Diagnostics Market
5.2.3.6.1 Italy Liver Disease Diagnostics Market by End User
5.2.3.6.2 Italy Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.7 Rest of Europe Liver Disease Diagnostics Market
5.2.3.7.1 Rest of Europe Liver Disease Diagnostics Market by End User
5.2.3.7.2 Rest of Europe Liver Disease Diagnostics Market by Diagnosis Technique
5.3 Asia Pacific Liver Disease Diagnostics Market
5.3.1 Asia Pacific Liver Disease Diagnostics Market by End User
5.3.1.1 Asia Pacific Hospitals Market by Country
5.3.1.2 Asia Pacific Laboratories Market by Country
5.3.1.3 Asia Pacific Other End Users Market by Country
5.3.2 Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
5.3.2.1 Asia Pacific Imaging Market by Country
5.3.2.2 Asia Pacific Biopsy Market by Country
5.3.2.3 Asia Pacific Endoscopy Market by Country
5.3.2.4 Asia Pacific Laboratory tests Market by Country
5.3.2.5 Asia Pacific Other Diagnosis Techniques Market by Country
5.3.3 Asia Pacific Liver Disease Diagnostics Market by Country
5.3.3.1 China Liver Disease Diagnostics Market
5.3.3.1.1 China Liver Disease Diagnostics Market by End User
5.3.3.1.2 China Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.2 Japan Liver Disease Diagnostics Market
5.3.3.2.1 Japan Liver Disease Diagnostics Market by End User
5.3.3.2.2 Japan Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.3 India Liver Disease Diagnostics Market
5.3.3.3.1 India Liver Disease Diagnostics Market by End User
5.3.3.3.2 India Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.4 South Korea Liver Disease Diagnostics Market
5.3.3.4.1 South Korea Liver Disease Diagnostics Market by End User
5.3.3.4.2 South Korea Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.5 Singapore Liver Disease Diagnostics Market
5.3.3.5.1 Singapore Liver Disease Diagnostics Market by End User
5.3.3.5.2 Singapore Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.6 Malaysia Liver Disease Diagnostics Market
5.3.3.6.1 Malaysia Liver Disease Diagnostics Market by End User
5.3.3.6.2 Malaysia Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.7 Rest of Asia Pacific Liver Disease Diagnostics Market
5.3.3.7.1 Rest of Asia Pacific Liver Disease Diagnostics Market by End User
5.3.3.7.2 Rest of Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
5.4 LAMEA Liver Disease Diagnostics Market
5.4.1 LAMEA Liver Disease Diagnostics Market by End User
5.4.1.1 LAMEA Hospitals Market by Country
5.4.1.2 LAMEA Laboratories Market by Country
5.4.1.3 LAMEA Other End Users Market by Country
5.4.2 LAMEA Liver Disease Diagnostics Market by Diagnosis Technique
5.4.2.1 LAMEA Imaging Market by Country
5.4.2.2 LAMEA Biopsy Market by Country
5.4.2.3 LAMEA Endoscopy Market by Country
5.4.2.4 LAMEA Laboratory tests Market by Country
5.4.2.5 LAMEA Other Diagnosis Techniques Market by Country
5.4.3 LAMEA Liver Disease Diagnostics Market by Country
5.4.3.1 Brazil Liver Disease Diagnostics Market
5.4.3.1.1 Brazil Liver Disease Diagnostics Market by End User
5.4.3.1.2 Brazil Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.2 Argentina Liver Disease Diagnostics Market
5.4.3.2.1 Argentina Liver Disease Diagnostics Market by End User
5.4.3.2.2 Argentina Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.3 UAE Liver Disease Diagnostics Market
5.4.3.3.1 UAE Liver Disease Diagnostics Market by End User
5.4.3.3.2 UAE Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.4 Saudi Arabia Liver Disease Diagnostics Market
5.4.3.4.1 Saudi Arabia Liver Disease Diagnostics Market by End User
5.4.3.4.2 Saudi Arabia Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.5 South Africa Liver Disease Diagnostics Market
5.4.3.5.1 South Africa Liver Disease Diagnostics Market by End User
5.4.3.5.2 South Africa Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.6 Nigeria Liver Disease Diagnostics Market
5.4.3.6.1 Nigeria Liver Disease Diagnostics Market by End User
5.4.3.6.2 Nigeria Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.7 Rest of LAMEA Liver Disease Diagnostics Market
5.4.3.7.1 Rest of LAMEA Liver Disease Diagnostics Market by End User
5.4.3.7.2 Rest of LAMEA Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肝疾患診断の世界市場2020-2026:エンドユーザー別(病院、研究所、その他)、診断技術別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆